CDX
Click for more information
10.0% 11.3¢ cardiex limited

Media thread, page-161

  1. Bewlidered1976
    172 Posts.
    lightbulb Created with Sketch. 27
    clock Created with Sketch.
    03/06/22
    08:23
    Post #: 61794047
    CardieX has gets hearts racing after independent equities research shop MST Access placed a $1.50 valuation on the Australian cardiovascular medtech.

    https://unauthorised investment advice/health/cardiex-gets-hearts-racing-as-mst-access-reaffirms-value-at-5x-current-share-price/?utm_medium=email&utm_campaign=*%20Morning%20Newsletter-06-02-2022&utm_content=httpsstockheadcomauhealthcardiexgetsheartsracingasmstaccessreaffirmsvalueat5xcurrentshareprice&utm_medium=email&utm_campaign=Morning%20email%20Friday%20June%203&utm_content=Morning%20email%20Friday%20June%203+CID_495cbffc7c2d9b2ee236d321304ebc56&utm_source=Campaign%20Monitor&utm_term=CardieX%20gets%20hearts%20racing%20as%20MST%20Access%20reaffirms%20value%20at%205x%20current%20share%20price

    CardieX has gots hearts racing after independent equities research shop MST Access placed a $1.50 valuation on the Australian cardiovascular medtech.

    The price equates to an overall market cap of about $165 million versus $32 million currently, as the company is currently trading just below 30c a share on market.

    MST is the second leading analyst to put a buy on CardieX in the last six months. In December, with a “spec buy” recommendation and target price of 16 cents. This was on a pre-consolidation basis equating to a target price of $1.60.

    Blue Ocean highlighted “early-stage growth potential and the impending nature of the FDA clearance process for the new product suite” which MST Analyst Chris Kallos also notes, flagging that the US FDA’s recent classification of the CONNEQT App as a Medical Device Data System paved the way for the launch of several consumer-facing products over the next six months.

    “The app will link all CONNEQT products in a new digital ecosystem based on devices using ATCOR’s SphygmoCor® technology,” he says.

    Commercialisation booster

    CardieX last year pivoted into the consumer health space and is working on commercialising a range of wearable, consumer health apps and home health devices .

    The company is booking more revenues following a 5% quarter-over-quarter increase in cash receipts to roughly $1.1 million at the end of the March quarter. This boosted CardieX’s cash balance to $3.9 million as of March 31, 2022.

    Kallos also noted that product development and operating costs were down $320,000 primarily due to prepaid inventory costs for new products in the prior quarter.

    CardieX subsidiary ATCOR Medical’s split into two distinct companies – ATCOR and CONNEQT – last year was part of the company’s move to .

    In March this year – a world-first consumer smartwatch incorporating ATCOR’s FDA-cleared SphygmoCor® heart-health technology.

    Users can monitor their own heart

    “This is the first commercial implementation of ATCOR’s heart monitoring technology in a wearable device,” Kallos says.

    This coupled with continued advancement towards securing FDA clearance for the CONNEQT Pulse and the CONNEQT Band products in the next financial year and a new clinical trial services agreement with Andwin Scientific has prompted MST Access to reaffirm its valuation.

    “We retain our fair value estimate for CardieX at $1.50 per share based on shares on issue of 109.9m (following the 10 for 1 consolidation),” Kallos says in the just released research note.

    “This represents a significant premium to the current share price of $0.28 per share.”

    The CONNEQT Pulse is anticipated to be the world’s first consumer vital signs monitor to include central blood pressure and other advanced arterial health biometrics, while the CONNEQT Band is a new wearable device focused on arterial health and incorporating similar biometric parameters as the Pulse.

    Kallos said the launch of both products should support integration of all products within a digital ecosystem.

    This article was developed in collaboration with CardieX, a * advertiser at the time of publishing

    This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

    Last edited by Bewlidered1976: 03/06/22
    CDX Price at posting: 28.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 16  Upvote
    lightbulb Created with Sketch. 3  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Update on the ASX' most anticipated drill campaign
right-arrow Created with Sketch.
NEWS Imugene kicks off Australian trial for blood cancer treatment
right-arrow Created with Sketch.
NEWS Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
right-arrow Created with Sketch.
NEWS HotCopper Highlights: Your most watched and most discussed stocks this week
right-arrow Created with Sketch.
EQN Equinox Resources reports outstanding naturally occurring antimony grade at Alturas Project
right-arrow Created with Sketch.
3DA To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels
right-arrow Created with Sketch.
watchlist Created with Sketch. Add CDX (ASX) to my watchlist
(20min delay)
Last
11.3¢ 		Change
-0.013(10.0%) 		Mkt cap ! $33.83M
Open High Low Value Volume
13.0¢ 13.0¢ 11.3¢ $68.99K 583.1K

Buyers (Bids)

No. Vol. Price($)
2 516056 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 55465 4
View Market Depth
Last trade - 14.07pm 11/11/2024 (20 minute delay) ?
CDX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.